The Greatest Guide To P-gb-IN-1
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge numerous intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Main trial targets were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyosi